Key result
Subsegmental PE shows no difference in VTE recurrence risk versus central PE in lung cancer.
Why the study?
The clinical significance of lung cancer-associated subsegmental pulmonary embolism remains unclear.
Does subsegmental pulmonary embolism carry a different risk of VTE recurrence and all-cause death compared to more central pulmonary embolism in patients with lung cancer?
Population
902 patients with lung cancer-associated PE
Comparison
160 subsegmental PE vs 742 more central PE
Design
Retrospective study
Authors
Loading...
Comparable recurrence risk suggests subsegmental PE may not warrant distinct management in lung cancer; leaves open optimal anticoagulation strategies pending randomized data.
Cohort (n=902)
Does subsegmental pulmonary embolism carry a different risk of VTE recurrence and all-cause death compared to more central pulmonary embolism in patients with lung cancer?
Hazard Ratio: 0.99 (95% CI 0.62–1.57)
p-value: p=0.95
In patients with lung cancer, subsegmental pulmonary embolism carries a similar risk of VTE recurrence and death as more central PE, and anticoagulation significantly reduces VTE recurrence in the subsegmental PE group.
Yang et al. (2025) conducted a cohort in Lung cancer-associated pulmonary embolism (n=902). Subsegmental pulmonary embolism vs. More central pulmonary embolism was evaluated on VTE recurrence (HR 0.99, 95% CI 0.62-1.57, p=0.95). Subsegmental pulmonary embolism in lung cancer patients showed no significant difference in VTE recurrence risk compared to more central pulmonary embolism (HR 0.99; 95% CI 0.62-1.57; p=0.95).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: